The Journal of Immunology, Vol 143, Issue 6 1868-1874, Copyright © 1989 by American Association of Immunologists

ARTICLES

Further studies of the role of transforming growth factor-beta in human B cell function

JH Kehrl, AS Taylor, GA Delsing, AB Roberts, MB Sporn and AS Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

This study was designed to address three specific questions in human B cells. First, to determine whether transforming growth factor-beta (TGF- beta)2 has similar biologic effects on B cell function as does TGF-beta 1. Second, to test the hypothesis that TGF-beta 1 is an autocrine growth and differentiation inhibitor. Finally, because multiple receptor species for TGF-beta have been identified on other cell types, to determine by chemical cross-linking and competitive binding studies the nature of the TGF-beta 1 R present on normal and transformed B cells. Exogenous TGF-beta 2 was found to be functionally similar to TGF- beta 1 in its inhibition of factor dependent normal B cell proliferation and Ig secretion. When an antibody, specific for the active form of TGF-beta 1, was added in conjunction with IL-2 to previously stimulated B cell cultures, there was a 14.4 +/- 4.2% increase in B cell proliferation, a 22 +/- 6% increase in IgG production, and a 33 +/- 8.6% increase in IgM production when compared to control cultures. Chemical cross-linking of 125I-TGF-beta 1 to normal B cell membranes identified two major cross-linked species of 65 and 90 kDa. A fivefold excess of unlabeled TGF-beta 1 competitively inhibited the detection of both of these bands while a 50-fold excess of unlabeled TGF-beta 2 did not inhibit the 90-kDa band and only partially inhibited (60%) of the 65-kDa band. Chemical cross-linking of 125I-TGF-beta 1 to transformed B cell membranes identified only a single band of 60 kDa. Scatchard plot analysis of 125I-TGF-beta 1 binding to normal B cells that was competitively inhibited with increasing concentrations of unlabeled TGF-beta 1 revealed both high and low affinity binding sites whereas analysis of 125I-TGF-beta 1 binding in the presence of increasing concentrations of unlabeled TGF- beta 2 revealed only low affinity sites. These findings demonstrate that TGF-beta 2 is as effective as TGF-beta 1 in inhibiting human B cell function, that small amounts of active TGF-beta 1 are present endogenously in in vitro cultures which partially inhibit B cell function, that two major TGF-beta 1 R cross-linked complexes of 65 and 90 kDa are present on normal B cells, and that transformation of B cells may be accompanied by changes in the TGF-beta 1 R.

This article has been cited by other articles:

				G. J. Inman and M. J. Allday Apoptosis Induced by TGF-{beta}1 in Burkitt's Lymphoma Cells Is Caspase 8 Dependent But Is Death Receptor Independent J. Immunol., September 1, 2000; 165(5): 2500 - 2510. [Abstract] [Full Text] [PDF]

				G. J. Inman and M. J. Allday Resistance to TGF-{beta}1 correlates with a reduction of TGF-{beta} type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines J. Gen. Virol., June 1, 2000; 81(6): 1567 - 1578. [Abstract] [Full Text]

				F. W. v. Ginkel, S. M. Wahl, J. F. Kearney, M.-N. Kweon, K. Fujihashi, P. D. Burrows, H. Kiyono, and J. R. McGhee Partial IgA-Deficiency with Increased Th2-Type Cytokines in TGF-{beta}1 Knockout Mice J. Immunol., August 15, 1999; 163(4): 1951 - 1957. [Abstract] [Full Text] [PDF]

				G. Bellone, A. Turletti, E. Artusio, K. Mareschi, A. Carbone, D. Tibaudi, A. Robecchi, G. Emanuelli, and U. Rodeck Tumor-Associated Transforming Growth Factor-{beta} and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients Am. J. Pathol., August 1, 1999; 155(2): 537 - 547. [Abstract] [Full Text] [PDF]

				M. Yano, B. N. Mora, J. M. Ritter, R. K. Scheule, N. S. Yew, T. Mohanakumar, and G. A. Patterson EX VIVO TRANSFECTION OF TRANSFORMING GROWTH FACTOR-{beta}1 GENE TO PULMONARY ARTERY SEGMENTS IN LUNG GRAFTS J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 705 - 713. [Abstract] [Full Text] [PDF]